Plasma Concentration of Tamoxifen and Its Metabolites in a Neonate and Mother Receiving Tamoxifen: A Case Report of a Pregnant Woman

Konishi, Kuniyoshi; Miyazono, Yayoi; Doki, Kosuke; Kido, Takahiro; Hitaka, Daisuke; Kanai, Yu; Takada, Hidetoshi; Homma, Masato

doi:10.1097/ftd.0000000000000608

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood concentrations of tamoxifen and its metabolites (N-desmethyl tamoxifen, 4-hydroxy tamoxifen, endoxifen) were determined in the mother and the infant at 3-4 hours after birth. The details of drug concentration have been reported before [ 4 ]. Similar blood concentrations were observed in mother and infant, confirming mother-to-fetus tamoxifen transmission; to the best of our knowledge, this is the first time this confirmation has been made.…”

Section: Case Presentationmentioning

confidence: 99%

“…is is the first follow-up report on an infant who was exposed to tamoxifen during the fetal period, with a definite level of tamoxifen and its metabolites seen in the blood just after delivery [4].…”

Section: Introductionmentioning

confidence: 99%

“…In the present study, we report an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. This is the first follow-up report on an infant who was exposed to tamoxifen during the fetal period, with a definite level of tamoxifen and its metabolites seen in the blood just after delivery [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen

Okada

Hitaka

Kido

et al. 2020

Case Reports in Pediatrics

Self Cite

View full text Add to dashboard Cite

Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies. This case presents detailed information on the development of an infant with placental transfer of tamoxifen. The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues.

show abstract

Section: Case Presentationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%